Trautmann M, Wiedeck H, Ruhnke M, Oethinger M, Marre R
Abteilung für Med. Mikrobiologie und Hygiene, Universität Ulm, Germany.
Infection. 1994 Nov-Dec;22(6):430-6. doi: 10.1007/BF01715507.
The teichomycin antibiotics have been discovered and chemically purified in the late 1970s. Teicoplanin, one of the major derivatives of this group, has been introduced into clinical use in 1984. In Germany, teicoplanin was licensed in 1988 and now ranks among the antimicrobial agents most frequently used in intensive care units. Due to its reduced rate of side effects compared to vancomycin, its longer serum half-life and a simplified mode of application, teicoplanin has become the glycopeptide of choice in many hospitals. The present review summarizes in vitro activity data, pharmacokinetics, and clinical experience with teicoplanin, with special consideration of currently recommended doses and serum levels.
替考拉宁类抗生素于20世纪70年代末被发现并进行了化学提纯。替考拉宁是该类主要衍生物之一，于1984年被引入临床使用。在德国，替考拉宁于1988年获得许可，目前是重症监护病房中最常用的抗菌药物之一。由于与万古霉素相比，其副作用发生率较低，血清半衰期较长，且应用方式简化，替考拉宁已成为许多医院首选的糖肽类药物。本综述总结了替考拉宁的体外活性数据、药代动力学和临床经验，并特别考虑了当前推荐的剂量和血清水平。
